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http://dx.doi.org/10.1016/j.hkjn.201
1561-5413/Copyright ª 2015, Hong KoAbstract Patients with cardiorenal syndrome (CRS) suffer from extremely high levels of
morbidity and mortality. The pathophysiology of the CRS involves inter-related hemodynamic
and neurohormonal mechanisms including the renineangiotensinealdosterone system (RAAS),
endothelin, and arginineevasopressin system activation. The management of CRS remains a
challenge despite extensive research into the pathophysiology, discovery of new biomarkers,
and ongoing drug trials. This article reviews some of the most important trials for patients with
acute decompensated heart failure and CRS using diuretics, vasodilator, levosimendan (a cal-
cium sensitizer), vasoactive and neurohormonal therapies, and finally ultrafiltration for refrac-
tory cases. In addition, the trials of a new agent that combines angiotensin-receptor blockade
with neprilysin inhibition (enhancing endogenous natriuretic peptide action), and of a new re-
combinant human relaxin-2 called serelaxin are discussed. For chronic CRS, the blockade of
the RAAS and levosimendan given in repetitive dosing is discussed. Finally, some data on
how the newer generation devices such as left ventricular assist device may improve outcome
of CRS are presented; additionally, some new ideas about prevention and treatment of
calcification-induced congestive cardiac failure in renal patients are presented.
心腎綜合症(CRS, cardiorenal syndrome)是嚴重的疾病，死亡率極高，其致病過程涉及一系列血
行動力-神經內分泌機轉的變化，包括腎素-血管緊縮素-醛固酮系統(RAAS, renineangiotensin
ealdosterone system)、內皮素(endothelin)及抗利尿素(arginineevasopressin)系統的活化。至
今，即使已有大量關於病理生理學、生物標識物、及藥物治療的研究問世，然而CRS仍然是臨床
上的一大挑戰。本文將針對合併有CRS的急性失代償性心衰竭 (ADHF)患者，回顧利尿劑、血管擴
張劑、levosimendan (鈣增敏劑)、血管活性及神經內分泌療法的相關重要研究，更會回顧超過
濾(UF, ultrafiltration)在頑抗性個案間的治療表現。此外，我們亦會探討利鈉肽(NPs, natriuretic
peptides)或神經荷爾蒙藥物的潛在效用，包括一種兼具血管緊縮素受體阻斷(ARB)與neprilysin抑
制作用(促進內源性NP活動)的新藥物、及一種新的重組人類relaxin-2 (稱為serelaxin)。至於慢性
CRS，我們主要著眼於RAAS阻斷劑與levosimendan的重複給藥、及腹膜透析(PD)療法。最後，我
們將回顧新世代裝置例如左心室輔助裝置(LVAD)對CRS的潛在效用，更會對腎病患者間，鈣化誘
發鬱血性心衰竭(CCF)的預防與治療作出探討。ersity of Hong Kong-Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
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Chronic kidney disease (CKD) is very common in patients
with heart failure (HF). In the Acute Decompensated Heart
Failure National Registry (ADHERE),1 >60% of 118,465 pa-
tients admitted to U.S. hospitals with acute decom-
pensated HF (ADHF) had Stage 3 [estimated glomerular
filtration rate (eGFR) < 60 mL/min/1.73 m2] or worse CKD.
Furthermore, during the treatment of ADHF, a significant
proportion of patients develop varying degrees of wors-
ening renal function (WRF). In a study of approximately
1000 patients admitted with ADHF, the serum creatinine
level increased by > 0.1 mg/dL (8.8 mmol/L) in >70% of
patients and by > 0.5 mg/dL (44 mmol/L) in up to 20% of
patients within 3 days of hospitalization.2 In 2008, a
consensus conference under the auspices of the Acute
Dialysis Quality Initiative3 agreed to classify the syndrome
into five distinct types depending on whether heart or
kidney was the initial organ of injury. In cardiorenal syn-
drome (CRS) Types 1 and 2, worsening of HF in acute (Type
1) or chronic HF (Type 2) leads to worsening of kidney
function. In Types 3 and 4 (termed acute and chronic
renocardiac syndromes, respectively), acute kidney injury
(AKI) or CKD leads to worsening HF. In Type 5 CRS, systemic
conditions cause simultaneous dysfunction of the heart and
kidney. In most studies, a rise in serum creatinine level of
0.3 mg/dL (26 mmol/L) or a 25% increase from baseline is
used to define acute or Type 1 CRS. Using this definition,
the prevalence of Type 1 CRS has been reported in the
27e45% range.4,5 The prevalence of Type 2 CRS is around
32e50% in large chronic HF trials.6e8 This review is pre-
dominantly based on a discussion of Types 1 and 2 CRS. The
five subtypes of CRS are presented in Table 1.
In CRS, the impaired forward flow and decreased
effective circulating volume in case of severe systolic HF or
cardiogenic shock lead to arterial underfilling and activa-
tion of neurohormonal and inflammatory pathways,
resulting in fluid retention and increase in venous pressure
(VP) and important repercussions on renal perfusion.
Autoregulation of the GFR fails and kidney functionTable 1 Classification of the five subtypes of cardiorenal
syndrome.
Type 1 A rapid worsening of cardiac function leading to
acute kidney injury
Type 2 Chronic abnormality in cardiac function
(e.g., congestive cardiac failure) leading to
progressive chronic kidney disease (CKD)
Type 3 An abrupt and primary worsening of kidney
function (e.g., ischemia) leading to acute
cardiac dysfunction (e.g., heart failure)
Type 4 CKD (e.g., chronic glomerulonephritis) as the
cause of decreased cardiac function (e.g., left
ventricular hypertrophy, diastolic dysfunction,
chronic heart failure)
Type 5 Presence of combined cardiac and renal
dysfunction due to acute or chronic systemic
disorders
CKD Z chronic kidney disease.declines, subsequently leading to worsening fluid retention,
preload, and afterload. A series of maladaptive responses
including the activation of the
renineangiotensinealdosterone system (RAAS), tubuloglo-
merular feedback, and activation of sympathetic nervous
system occur in HF.9 Furthermore, venous congestion and
high right-sided pressure, such as in the case of HF with
preserved ejection fraction (EF) or isolated right HF, may
lead to decreased arteriovenous perfusion gradient,
increased kidney interstitial edema, and worsening of fluid
retention.9,10A higher central VP (CVP) was found to be
inversely related to GFR and independently associated with
all-cause mortality.11 Moreover, an incremental risk of
developing WRF with increasing CVP was observed in pa-
tients with ADHF independent of the cardiac output (CO).
Thus, further understanding of the role of increased VP in
CRS may provide future novel drug targets and gauge
therapeutic efficacy.
CRS is a systemic illness that results from the interplay
among myocardial factors, systemic inflammation, renal
dysfunction, and neurohormonal activation including
adenosine, endothelin, and decreased response to atrial
natriuretic peptide (ANP). Insights into the pathophysiology
of HF have allowed the identification of several biomarkers
that represent key disease pathways. Among others,
promising biomarkers identified for this purpose include
cystatin C, neutrophil gelatinase-associated lipocalin
(NGAL), N-acetyl-b-D-glucosaminidase, and kidney injury
molecule-1.12e14 The application of these biomarkers may
provide future therapeutic modifications aiming at an
earlier stage, thereby attenuating further damage to the
kidneys.Worsening renal function
Several studies have demonstrated that WRF during the
treatment of ADHF leads to increased mortality.15,16 Renal
dysfunction is a major independent risk factor for mortality
in patients with postinfarction left ventricular dysfunction
and HF, as shown in the Survival And Ventricular Enlarge-
ment (SAVE) trial.17 These data were subsequently
confirmed by the results of other trials, including the
Candesartan in Heart Failure Assessment of Reduction in
Mortality and Morbidity trial,7 which showed that the
relationship between kidney dysfunction and poor outcome
was present regardless of EF. Data from the ADHERE study1
showed that blood urea nitrogen (BUN), serum creatinine,
and systolic blood pressure (BP) were strong predictors of
in-hospital mortality in acute HF patients. However, the use
of serum creatinine rise as a marker of WRF is not ideal. For
example, the early rise of serum creatinine level following
the introduction of an angiotensin-converting enzyme in-
hibitor (ACEI) reflects changes in glomerular hemodynamics
and does not translate to a worse outcome. This was illus-
trated by the limited data set analysis of the Studies of Left
Ventricular Dysfunction (SOLVD), which was undertaken to
examine the interactions between early WRF (decrease in
eGFR  20% at 14 days), randomization to enalapril, and
mortality end point in 6377 patients.18 In total, 606 patients
(9.5%) experienced early WRF between baseline and 14
days after randomization with a mean decrease in eGFR of
38 P. Pai29.2  9.8% in the enalapril group and 28.9  9.3% in the
placebo group. In the overall population, early WRF was
associated with increased mortality [hazard ratio (HR) 1.2,
95% confidence interval (CI) 1.0e1.4; pZ 0.037], however,
it had no adverse prognostic significance in the enalapril
group (HR 1.0, 95% CI 0.8e1.3; p > 0.99, p
interaction Z 0.09), which showed a survival advantage
over placebo (HR 0.66, 95% CI 0.5e0.9; p Z 0.018).18
In the Placebo-Controlled Randomized Study of the Se-
lective Adenosine A1 Receptor Antagonist Rolofylline for
Patients Hospitalized with Acute Decompensated Heart
Failure and Volume Overload to Assess Treatment Effect on
Congestion and Renal Function (PROTECT) trial,19 it was
shown in a subset of 1969 patients with acute HF, mild to
moderate renal dysfunction, and serial hemoglobin (Hb)
measurements that hemoconcentration was associated
with higher serum albumin, greater weight loss, and less
residual congestion on Day 7 (41.1% vs. 53.2%, p < 0.01) but
a higher serum creatinine.20 Despite the increase in serum
creatinine, patients with hemoconcentration experienced
lower rates of all-cause mortality at 180 days, which in-
dicates better decongestion than those without hemo-
concentration. In a multivariable analysis adjusted for age
and renal function, the absolute change in Hb (i.e.,
hemoconcentration), and not baseline Hb, was associated
with the risk of death (HR 0.66, 95% CI 0.51e0.86;
p < 0.002).Diuretic treatment
Diuretics remains themainstay of acute HF therapy, however
they contribute to the development of WRF, especially when
administered in high doses. The post hoc analysis of the
Evaluation Study of Congestive Heart Failure and Pulmonary
Artery Catheterization Effectiveness (ESCAPE) demon-
strated a robust relationship between diuretic dose and
mortality.21 However, on further analysis of the available
data of 336 patients with a baseline/discharge pair of he-
matocrit, albumin, or total protein values, it was apparent
that aggressive decongestion substantially improved survival
at 180 days (HR formortality, 0.31; pZ 0.013).22 In relatively
less severe cases with a higher probability of survival, how-
ever, WRF might generate a vicious cycle leading to further
aggravation of kidney injury and to adverse clinical out-
comes in the medium to long term.
The Diuretic Optimization Strategies Evaluation (DOSE)
trial is one of the few recently published large prospective
studies in this field.23 DOSE was a prospective, double-
blind, randomized controlled trial (RCT) that randomized
308 patients with ADHF into four different regimens of
intravenous (IV) furosemide, either in bolus every 12 hours
or by continuous infusion, and at either low (pre-existing
oral dose) or high doses (2.5-fold oral dose). Coprimary end
points were symptoms score and change of renal function
(i.e., serum creatinine levels) at 72 hours. The trial did not
show significantly different outcomes for bolus versus
continuous infusion or between high- and low-dose groups.
A near-significant trend (p Z 0.06) was observed for
symptomatic improvement in the high- versus low-dose
groups, alongside a greater diuresis and transient WRF.
Overall, there were no differences with respect to theapplication route or the dosage of the diuretic on the
coprimary end points. High-dose therapy led to a faster
relief of dyspnea and a greater loss of fluid and weight at
the cost of a more pronounced, transient WRF. The DOSE
trial thus challenges the widely held belief that high-dose
diuretic therapy worsens renal function and thus worsens
outcomes. Therefore, a short-term diuretic treatment
intensification, aimed at relieving congestion in ADHF pa-
tients, may provide long-term cardiovascular (CV) benefits.
Efforts have been focused on finding alternative thera-
pies that allow freedom from congestion without precipi-
tating WRF. Some researchers were searching for
biomarkers other than serum creatinine to define WRF that
distinguishes CRS and renal injury from WRF due to hemo-
concentration/hemodynamic effect. According to a single-
centered study of 119 patients with acute HF, a single
plasma NGAL measurement above a cutoff value of 170 ng/
L (from the 1st day onward) could identify all patients
developing Type 1 CRS within 48e72 hours with a 50% false-
positive rate.14 An NGAL value less than the cutoff value of
170 ng/L has a negative predictive value of 100%. However,
at present, the role of novel biomarkers in clinical trials
remains unproven and further studies are required to
elucidate their characteristics and validity as related to
established HF end points.
The persistence of renal vasoconstriction, tubuloglo-
merular feedback, actions of vasoactive peptides (e.g.,
adenosine and endothelin), and diminished response to
endogenous NP are important pathophysiological compo-
nents of diminished GFR in HF.9 Some of the earlier trials of
these agents including nesiritide, vasopressin V2-receptor
antagonist, and adenosine 1 (A1)-receptor antagonist
were showing early promise.24 Other treatment strategies
for chronic CRS including b-blocker and anemia correction
using erythropoietin have also been reviewed.24 In this re-
view, an update on the pharmacological and mechanical
approaches for treatment of Types 1 and 2 CRS is provided.
Vasopressin V2-receptor antagonist
Tolvaptan is a selective vasopressin V2-receptor antagonist
that acts on the distal nephron, causing loss of electrolyte-
free water. In the randomized, placebo-controlled study of
the Efficacy of Vasopressin Antagonism in Heart Failure
Outcome Study with Tolvaptan (EVEREST), patients with
ADHF were given tolvaptan or placebo in addition to stan-
dard treatment.25 Patients with serum creatinine levels
>3.5 mg/dL (308 mmol/L) were excluded. Although tol-
vaptan reduced many signs and symptoms of HF and
improved hyponatremia without significant adverse effects
on BP or renal function, there was no significant benefit
with respect to mortality or hospitalization rate. Currently,
according to the American guideline26 (Class IIb, level of
evidence B), tolvaptan may be used for short-term treat-
ment of severe hyponatremia associated with ADHF and
volume overload.
Natriuretic peptides
Nesiritide, a recombinant human brain natriuretic peptide
(BNP), is a venous and arterial vasodilator with modest
Cardiorenal syndrome 39diuretic and natriuretic effects. Nesiritide has been used
for a long time in the ADHERE.1 In the Vasodilation in the
Management of Acute Congestive Heart Failure (VMAC)
trial, 489 patients with acute congestive cardiac failure
(CCF) were randomized to receive nesiritide versus nitro-
glycerin versus placebo. Nesiritide showed an improvement
of dyspnea and a reduction in pulmonary capillary wedge
pressure (PCWP) at 3 hours compared with placebo.27 The
placebo-controlled Acute Study of Clinical Effectiveness of
Nesiritide in Decompensated Heart Failure (ASCEND-HF)
randomized 7141 acute HF patients to receive nesiritide or
placebo. Treatment with nesiritide showed a small but
nonsignificant benefit on dyspnea at 6 hours and 24 hours,
respectively, without any effect on the composite end point
of rehospitalization for HF or death within 30 days.28 There
was also a significant increase in hypotension. In the Renal
Optimization Strategies Evaluation study in Acute Heart
Failure (ROSE-AHF),29 a lower dose (0.005 mg/kg/min) of
nesiritide (one half of the dose tested in ASCEND-HF) was
tested in patients with CCF and kidney dysfunction (eGFR
15e60 mL/min/1.73 m2) and compared with low-dose
dopamine (2 mg/kg/min) and placebo for 72 hours, in
addition to standard diuretic therapy. There were a total of
360 patients. Even then, hypotension was common in the
nesiritide-treated patients. The coprimary end points were
72-hour cumulative urine volume (decongestion end point)
and change in serum cystatin C from enrollment to 72 hours
(renal function end point). Neither dopamine nor low-dose
nesiritide appeared to enhance decongestion or preserve
renal function. In the absence of hypotension, nesiritide
may be considered as an adjuvant to relieve acute dyspnea
in ADHF cases (Class IIb, level of evidence A).26
A1-receptor antagonist (rolofylline)
Adenosine was thought to be an important mediator of WRF
and diuretic resistance in HF. It stimulates renin release
through stimulation of its A1 receptor and reduces GFR. It is
believed that in patients with HF, A1-receptor antagonists
may preserve GFR, enhance sodium excretion, and improve
diuretic responsiveness. The Placebo-Controlled Random-
ized Study of Selective Adenosine (A1)-Receptor Antagonist
Rolofylline for Patients Hospitalized with ADHF and Volume
Overload to Assess Treatment Effect on Congestion and
Renal Function (PROTECT) enrolled 2033 patients receiving
IV infusion of rolofylline or placebo.19 The mean creatinine
clearance was 50 mL/min/1.73 m2 (range 20e80 mL/min/
1.73 m2). Despite the favorable outcome of the pilot study,
the PROTECT study failed to reduce the primary end point
(mortality or rehospitalization due to renal or CV causes) or
secondary end point (persistent increase in serum creati-
nine on Day 7). Moreover, there was a concern about safety,
because 1% of the patients developed seizure, a known
adverse effect of A1-receptor antagonists owing to inhibi-
tion of the central A1 receptors.
Levosimendan use in Type 1 CRS
Levosimendan is an inotrope with a vasodilatory effect. It
has been in clinical use for decompensated HF for >10
years. Levosimendan exerts positive inotropic effect bybinding to cardiac troponin C, thereby increasing the sus-
ceptibility of myofilaments to calcium. Its vasodilatory ef-
fects are brought about by adenosine triphosphate-
dependent opening of potassium channels and phosphodi-
esterase inhibition. In contrast to other inotropes, levosi-
mendan acts independently of b-adrenergic receptors. It
has been shown to reduce proinflammatory cytokines and
BNP30 and preserve renal function.31
The renal effect of levosimendan was studied in 21 pa-
tients with ADHF and moderate renal impairment with a
PCWP >20 mmHg.32 An intravascular renal artery Doppler
examination was performed at baseline, after levosi-
mendan bolus, and 1 hour thereafter. The results were
significantly different from placebo in terms of renal blood
flow (pZ 0.037) with ensuing improvements in serum levels
of BUN (p Z 0.014), creatinine (pZ 0.042), and cystatin C
(p Z 0.05). Concomitantly, levosimendan provided a sig-
nificant increase in urine output up to 72 hours (p Z 0.02)
as well as favorable changes in cardiac index (p Z 0.029)
and PCWP (p < 0.001). However, the results of several
major clinical studies of levosimendan have been inconsis-
tent.33,34 In the Levosimendan Infusion versus Dobutamine
(LIDO) trial, levosimendan led to an increased hemody-
namic improvement that was associated with a lower risk of
mortality compared with dobutamine administered ac-
cording to a protocol-based regime.33 However, in the
larger, randomized Survival of Patients With Acute Heart
Failure in Need of Intravenous Inotropic Support trial
including 1327 patients hospitalized with ADHF requiring
inotropic support, levosimendan treatment did not improve
the 180-day mortality or any other secondary clinical
outcome compared with dobutamine administered ac-
cording to the clinical need.34 It was imaginable that the
differences in mortality in the LIDO study were not due to a
decrease in mortality with levosimendan, but rather due to
an increase in mortality with the use of dobutamine. A
further randomized study of 60 patients with ADHF on b-
blocker treatment showed that levosimendan was compa-
rable to dobutamine with respect to hemodynamic and
neurohormonal improvements, although there was a higher
rate of hypotension in the levosimendan group (10% vs.
2%).35 The European guideline36 has recommended the use
of levosimendan (Class IIb, level of evidence C) in patients
with acute HF on pre-existing b blockers.Levosimendan use in chronic advanced HF and
CRS
The use of repetitive levosimendan infusion as an outpatient
therapy in stable chronic advanced HF patients has caused
much interest.37 After a 24-hour infusion of levosimendan,
its pharmacodynamic effects (i.e., CO and PCWP) were
shown to persist for at least 1 week.38 In the Randomized
EValuation of Intravenous LeVosimendan Efficacy (REVIVE II)
trial,39 which compared levosimendan (bolus of 6e12 mg/kg
over 10 minutes followed by 0.1e0.2 mg/kg/min for 24
hours) with placebo, on top of standard care, in patients
with ADHF, the percentage of patients free of dyspnea
favored levosimendan over placebo for up to 5 days after the
completion of treatment. The LevoRep study40 was a large,
prospective, multicentered, randomized, placebo-
40 P. Paicontrolled, double-blind, two-armed, parallel-group study
carried out to examine the effect of repetitive, ambulatory
administration of levosimendan in advanced stable HF pa-
tients [New York Heart Association (NYHA) III/IV, left ven-
tricular ejection fraction  35%]. Patients were randomized
to receive placebo or levosimendan (0.2 mg/kg/min) for 6
hours at 2-week intervals for a total of four infusions in
addition to other HF therapy. At the end of 24 weeks, the
treatment group failed to reach the combined primary end
point for improvement in functional capacity of 20% ac-
cording to the 6-minute walk test, and improvement in pa-
tient quality of life of 15% as assessed by the Kansas City
Cardiomyopathy Questionnaire score. However, there was
an improved survival as part of the secondary end point after
24 weeks (17.4% vs. 35.1%, pZ 0.037).
Most reports on the effect of levosimendan indicated an
improvement of renal function in HF, however, the study
designs differed considerably.31 Importantly, in the largest
HF study (REVIVE I and II),39 no significant changes in renal
function were detected. In 2014, an expert consensus was
reached in that for stable chronic advanced HF patients,
levosimendan may be given as an infusion at a rate of
0.2 mg/kg/min, for 6e24 hours every 2e4 weeks, with a
view to improve symptoms while accepting that more
studies are required to determine any survival benefit.37Serelaxin and acute CRS
Serelaxin is a recombinant form of human relaxin-2. This is
a naturally occurring peptide hormone that increases dur-
ing pregnancy and mediates the maternal physiological CV
and renal adaptations and has potential protective effects
against organ damage.41 These biological effects suggest
that relaxin might be an ideal therapeutic agent in acute HF
where the opposite pathophysiological changes are
observed. Among other potential mechanisms, relaxin acts
by increasing the expression of endothelin-type B re-
ceptors, which have a clearance function for endothelin-1,
a potent vasoconstrictor. Therefore, relaxin is a functional
endothelin-1 antagonist.
In the randomized, placebo-controlled pre-RELAXin in
Acute Heart Failure (pre-RELAX-AHF) trial, treatment with
serelaxin significantly reduced dyspnea and the combined
end point of CV death or admission due to heart and renal
failure on Day 60.42 The phase III RELAX-AHF trial is another
RCT designed to compare serelaxin (nZ 581) with placebo
(n Z 580) in patients with acute HF.43 The median time
from presentation was 6 hours and patients were required
to have a systolic BP > 125 mmHg and elevated levels of NP
at the time of screening. The primary end point was eval-
uating dyspnea improvement using the visual analog scale
(VAS) from baseline to Day 5 and the proportion of patients
with moderate or marked dyspnea improvement using the
Likert scale during the first 24 hours. Secondary end points
were days survived out of the hospital up to 60 days and CV
death or rehospitalization due to heart or renal failure
within 60 days. Approximately 70% of patients in either
group had an eGFR < 60 mL/min/1.73 m2, and approxi-
mately 47% had an eGFR < 50 mL/min/1.73 m2. Within the
first 5 days, using VAS, treatment with serelaxin improved
the primary dyspnea end point compared with placebo.However, serelaxin did not reduce the rate of CV death or
HF readmissions up to Day 60 or affect the days alive out of
the hospital up to Day 60 (secondary end points). In a post
hoc analysis undertaken by Metra et al,44 serelaxin admin-
istration was associated with significant reduction of
markers of end-organ damage (cardiac, renal, and hepatic)
at Day 2 from randomization. There was also a 37% reduc-
tion in CV mortality after a follow-up period of 180 days in
the serelaxin group versus placebo with a larger reduction
in CV mortality and all-cause mortality being observed in
patients aged  75 years, and those with an eGFR < 50 mL/
min/1.73 m2. The result of an ongoing phase 3 study of 6300
patients is expected in 2016.Neprilysin
Neprilysin is a neutral endopeptidase that catalyzes the
degradation of a number of vasodilator peptides, including
ANP, BNP, bradykinin, substance P, and adrenomedullin,
and contributes to the breakdown of angiotensin II.45
Therefore, inhibiting this enzyme will augment the natu-
rally occurring NP. Neprilysin plays no role in the breakdown
of N-terminal prohormone of BNP (NT-proBNP). Because
neprilysin inhibitors may potentially increase circulating
angiotensin II levels, it provides a rationale for developing a
compound that dually blocks this enzyme and the RAAS.Angiotensin receptor neprilysin inhibitor trial
in chronic HF and CRS
The investigational drug LCZ696 is an angiotensin receptor
neprilysin inhibitor (ARNI) composed of two distinct phar-
macological moieties, namely, a neprilysin inhibitor prodrug
and the angiotensin-receptor blockade (ARB), valsartan.
The efficacy of LCZ696 as a treatment for HF with pre-
served EF was assessed in Prospective comparison of ARNI
with ARB on Management Of Heart Failure with Preserved
Ejection Fraction (PARAMOUNT), a phase II clinical trial
comparing the effect of LCZ696 versus valsartan.46 This
trial enrolled patients with EF of 45% who were classified
as NYHA Class IIeIII with NT-proBNP level >400 pg/mL. The
primary end point was change in NT-proBNP levels and a
measure of ventricular wall stress at baseline and at 12
weeks. LCZ696 was superior to valsartan in reducing NT-
proBNP at 12 weeks (p Z 0.005). After 36 weeks, NT-
proBNP levels remained reduced in the LCZ696 arm, how-
ever, reduction was also observed in the valsartan arm, so
that between-group treatment differences were no longer
significant [496 (401e613) pg/mL vs. 607 (484e760) pg/
mL]. However, patients receiving LCZ696 had significant
improvement of NYHA class and left atrial size compared
with those receiving valsartan at 36 weeks.
The Prospective Comparison of Angiotensin Recep-
toreNeprilysin Inhibitor with Angiotensin-Converting-
Enzyme Inhibitor to Determine Impact on Global Mortality
and Morbidity in Heart Failure Trial (PARADIGM-HF) was a
phase III, double-blind RCT that compared the effect of
LCZ696 versus enalapril in Class IIeIV chronic HF patients.47
Patients with an EF of 40% and an average serum creati-
nine level of 1.13  0.3 mg/dL (100  26 mmol/L) were
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times daily) or enalapril (at a dose of 10 mg 2 times daily) in
addition to recommended therapy. Patients with
BP < 100 mmHg or eGFR <30 mL/min/1.73 m2 at screening
were excluded. The trial was terminated early after a
median follow up of 27 months because the benefit of
LCZ696 exceeded the prespecified rules. At the time of
study closure, the primary outcome had occurred in 914
patients (21.8%) in the LCZ696 group and 1117 patients
(26.5%) in the enalapril group (HR for the LCZ696 group was
0.80; 95% CI 0.73e0.87; p < 0.001). A total of 711 patients
(17.0%) receiving LCZ696 and 835 patients (19.8%) receiving
enalapril died (HR for death from any cause was 0.84; 95%
CI 0.76e0.93; p < 0.001). Of these patients, 558 (13.3%)
and 693 (16.5%), respectively, died from CV causes (HR
0.80; 95% CI 0.71e0.89; p < 0.001). Compared with ena-
lapril, LCZ696 also reduced the risk of hospitalization for HF
by 21% (p < 0.001) and decreased the symptoms and
physical limitations of HF (p Z 0.001).
Prospective Comparison of ARNI with ARB Global Out-
comes in Heart Failure with Preserved Ejection Fraction
(PARAGON-HF) is an ongoing double-blind RCT that began in
late 2013 to compare prospectively ARNI with ARB global
outcomes in HF cases with preserved EF. It was designed to
enroll 4300 patients with signs and symptoms of chronic HF,
NYHA Class IIeIV, EF of >45%, a history of HF hospitalization
within 9 months or an elevated NT-proBNP level at entry, or
evidence of structural heart disease to either the LCZ696 or
valsartan group. Patients with eGFR < 30 mL/min/1.73 m2
were excluded. The primary outcome measures include CV
death and total HF hospitalizations.Renin inhibitor and mineralocorticoid receptor
antagonist
The use of aliskiren, a direct renin inhibitor, represents
another pharmacologically distinct method for RAAS
blockade with the theoretical benefit of upstream RAAS in-
hibition at the point of pathway activation. In the Aliskiren
Trial on Acute Heart Failure Outcomes (ASTRONAUT) trial,48
1639 stabilized HF patients (EF 40%) with elevated NP level
admitted to the hospital with symptoms and signs of fluid
overload were randomized to receive either aliskiren or
placebo in addition to standard treatment including an ACEI
(84.2%), b blocker (82.5%), and mineralocorticoid receptor
antagonist (MRA; 57.0%). Patients with an eGFR < 40 mL/
min/1.73 m2 or a serum potassium level >5 mmol/L were
excluded. Aliskiren did not reduce the combined primary
end point of CV death or hospitalization for HF at 6months or
12 months after discharge, although the NT-proBNP levels
were significantly and sustainably reduced. Comparing alis-
kiren with placebo, there were more adverse effects
including hyperkalemia (20.9% vs. 17.5%), hypotension
(17.1% vs. 12.65%), and renal dysfunction (16.6% vs. 12.1%).
On this note, it will be worth revisiting the data of the
Eplerenone Post-Acute Myocardial Infarction Heart Failure
Efficacy and Survival Study (EPHESUS) trial, which showed a
benefit of adding low-dose eplerenone, an MRA, to standard
therapy in acute myocardial infarction and HF patients with
left ventricular systolic dysfunction.49 Eplerenone
increased the survival by 15%. Further analysis of the studyundertaken by Rossignol and colleagues50,51 showed a WRF
in 16.9% of patients in the eplerenone group versus 14.7% of
patients in the placebo group after 1 month, however, the
eGFR change in the eplerenone group correlated positively
with the estimated plasma volume change indicative of a
hemodynamic process. Although eplerenone induced a
more frequent early decline in eGFR, it did not affect its
clinical benefit on CV outcomes.
Patients with diuretic refractoriness may benefit from
mechanical removal of fluid (ultrafiltration, UF). Two mo-
dalities of renal replacement therapy can be used in these
patients, namely, isolated UF and peritoneal dialysis (PD).Peritoneal dialysis
The clinical usefulness of PD as a maintenance therapy for
intractable chronic HF patients has been accumulating
since 1990s. Nakayama52 has recently undertaken a review
on the usefulness of PD as a chronic supportive therapy for
CRS Types 2 and 4. In the nonuremic predialysis setting of
chronic HF, PD was shown to improve cardiac function and
preserve residual renal function. In theory, the removal of
proinflammatory factors (e.g., tumor necrosis factor-a and
cardiac depressant factor) from the PD fluid might improve
cardiac function. It is likely that PD preserves residual
kidney function by slowing fluid removal, thus leading to
less stimulation of the renineangiotensin system or the
sympathetic nervous system, or both. Furthermore, Cour-
ivaud et al53 presented the largest cohort of patients with
chronic refractory HF (CRHF) in whom PD was initiated to
manage volume overload and diuretic refractoriness. The
retrospective analysis included 126 CRHF patients who
were treated with PD between 1995 and 2010 at two cen-
ters in France (Besanc¸on and Dunkerque). The mean age
was 72  11 years; the mean eGFR was 33.5  15.1 mL/
min/1.73 m2. Patients with eGFR < 15 mL/min/1.73 m2
were excluded. As much as 55% had an eGFR > 30 mL/min/
1.73 m2 (mean 45.5  12.7 mL/min/1.73 m2), 28% had an
eGFR of 20e30 mL/min/1.73 m2, and 17% had severe renal
dysfunction and an eGFR of 15e20 mL/min/1.73 m2 (mean
17.2  1.4 mL/min/1.73 m2). The causes of HF were
ischemic cardiomyopathy (62%), dilated cardiomyopathy
(52%), valvular cardiomyopathy (29%), and diastolic
dysfunction (10%). As much as 46% of the patients suffered
from atrial fibrillation. PD was associated with a dramatic
reduction in the number of days of HF-related hospitaliza-
tion after initiation of PD therapydfrom 3.3  2.6 d/mo to
0.3  0.5 d/mo (p < 0.0001). The 1-year mortality rate was
42%. The mean survival duration was 16  16 months (range
14 dayse8.4 years) with a trend toward lesser survival in
patients with an LVEF <30%. Overall, the LVEF improved
significantly during the 1st year of PD therapy (38  19% at
baseline vs. 42  17% at 1 year, pZ 0.001), and more so in
those with an LVEF of <30% (20%  6% at baseline vs. 30% 
10% at 1 year, p < 0.0001). The peritonitis rate was one
episode in 26.2 patient-months. Thus, PD therapy would
appear to be an appropriate and feasible option for CRHF
patients in whom conventional therapies have not resulted
in the desired therapeutic response, although prospective
analyses to elucidate the clinical significance and possible
risk of PD in patients with chronic HF are warranted.
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The earlier trials of UF have demonstrated its usefulness in
HF cases resistant to diuretics, however, these trials had
small patient groups and short follow ups. The Relief for
Acutely Fluid Overloaded Patients with Decompensated
Congestive Heart Failure Trial54 was a small, multicenter
RCT that compared the effects of a single, early, 8-hour UF
treatment strategy with diuretic therapy in patients hos-
pitalized for ADHF of any etiology. All patients experienced
an improvement in symptoms in 48 hours including global
congestive HF and dyspnea assessments, and more so in the
UF group; however, there was no significant difference
between weight losses in the two groups after 24 hours, a
primary end point.
The UF versus IV Diuretics for Patients Hospitalized for
Acute Decompensated Congestive Heart Failure Trial (UN-
LOAD) randomized 200 patients to UF versus diuretics
either given in bolus or continuously.55 Approximately 75%
of patients from each group had an EF of <40% on admis-
sion. The average serum creatinine level was 1.5  0.5 mg/
dL (132  44 mmol/L). The primary end points of the UN-
LOAD study were weight loss and patients’ dyspnea
assessment after 48 hours. Weight loss was more pro-
nounced in the UF arm compared with the standard-care
arm although the change in dyspnea score was similar.
There were significantly fewer secondary end points in the
UF group at 90 days, including rehospitalizations and un-
scheduled visits. There were no differences in serum
creatinine among the groups up to 90 days. The UNLOAD
trial has been criticized in terms of the suboptimal dose of
diuretics used, because according to the treatment proto-
col, the minimum dose of IV diuretics was planned to be at
least two times the before-hospitalization daily furosemide
(oral) dose of 119  116 mg, however, there was only a 50%
increase (i.e., 181  121 mg).56
After the UNLOAD trial, the Cardiorenal Rescue Study in
Acute Decompensated Heart Failure (CARRESS-HF) was
designed to compare the effects of UF at a fixed rate
(200 mL/h) with those of stepped pharmacologic therapy on
renal function and weight loss in HF patients with persistent
congestion.57 In this study, 188 patients with median EF of
30e35% were randomized to receive UF or diuretics. The
median eGFR was 1.9e2.09 mg/dL (range 167e184 mmol/
L). The primary end point was bivariate change from
baseline in the serum creatinine level and body weight, as
assessed 96 hours after randomization. In contrast to UN-
LOAD, which favored UF, the use of stepped pharmacolog-
ical therapy was more superior to UF in CARRESS-HF with
respect to the bivariate end point (p Z 0.003) owing pri-
marily to an increase in the serum creatinine level in the UF
group. There was also a nonsignificant increase in all-cause
readmission rate in the UF group. Because of a significantly
higher rate of serious adverse events including kidney
failure, bleeding complications, and catheter-related
complications associated with the UF arm, the trial was
terminated early. In the case of CARRESS-HF, it was com-
mented that the use of an individually tailored UF rate as
determined by refilling pressure would have been more
appropriate instead of the fixed UF rate of 200 mL/h.58 The
current guidelines recommend the use of UF in cases ofrefractory HF and volume overload to alleviate congestive
symptoms (Class IIb, level of evidence B) or in patients
resistant to diuretics (Class IIb, level of evidence C).26,36,59
It has been observed that the amount of fluid subtrac-
tion estimated on the basis of weight loss during hospital-
ization for ADHF appeared to bear no relationship with
clinical improvement as defined on the basis of the degree
of fatigue and dyspnea.60 Furthermore, tolvaptan produced
an important weight reduction in HF but the reduced fluid
volume did not translate into a sustained improvement in
symptoms.61 These observations support fluid redistribution
as a cause of pulmonary congestion rather than net fluid
gain as the critical event precipitating symptom in ADHF, a
phenomenon depending on arterial and venous constriction
induced by neural and endocrine mechanisms, inflamma-
tion, and kidney dysfunction.58 In ADHF and CRS, the
monitoring of lung water by ultrasound scan and/or bio-
impedance may provide a better opportunity in establishing
whether and when UF may be advantageous when
compared with diuretic treatment.58Left ventricular assist device
Left ventricular assist device (LVAD) has been increasingly
used as a bridge to heart transplant or as a “designation
treatment” for those unsuitable for receiving a transplant
(Class IIa, level of evidence B).26 In the United States,
approximately 2000 devices are being inserted annually.
The device is divided into pulsatile and continuous flow; the
latter is smaller, less noisy, and more durable and is being
used in 95% of the cases. Many patients receiving these
devices have underlying renal dysfunction varying from
mild, moderate, to severe; 4917 patients belonging to the
Interagency Registry for Mechanically Assisted Circulatory
Support were studied in retrospect.62 As much as 30% of the
patients had moderate to severe renal dysfunction and 6%
had severe renal dysfunction following LVAD implantation.
Compared with patients with mild or moderate renal
dysfunction, patients with severe renal dysfunction were
more likely to develop respiratory failure, cardiogenic
shock, right ventricular failure, hepatic dysfunction, and to
die within the first 3 months of receiving an implant.
However, in survivors, there was usually a significant
improvement of eGFR and reduction in various neuroen-
docrine components such as ANP, renin, and aldosterone.62
In a single-center analysis undertaken in retrospect by
Hasin et al,63 83 LVAD patients were assessed for their renal
function before and after implantation. For the majority of
the patients, there was an increase in eGFR after LVAD,
indicating an hemodynamic response. The mean eGFR
increased significantly 1 month post-LVAD implantation
(87.4  27.9 mL/min/1.73 m2) compared with baseline
(53.2  21.4 mL/min/1.73 m2; p < 0.0001). Interestingly, at
3 months and 6 months, there was a partial decline of eGFR
compared with the 1-month post-LVAD period, however,
the mean eGFR remained significantly above the pre-LVAD
values (p < 0.0001). Of the 51 patients with eGFRs <
60 mL/min/1.73 m2 before LVAD implantation surviving at 1
month, the eGFRs improved to >60 mL/min/1.73 m2 in 34
(67%) patients. The predictors for reversibility of renal
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and the use of intra-aortic balloon pump. Eight patients
developed AKI requiring dialysis support. Only two of these
eight patients had their renal function recovered, two died,
and four required long-term dialysis therapy. It was not
known whether LVAD had directly contributed to the kidney
injury after the implantation. Mild hemolysis is common
due to mechanical cause after LVAD, with a case of severe
hemolytic uremic syndrome being reported.64
Calcification
Finally, the association between CKD and calcification and
CV disease has been established. It is believed that phos-
phate plays a direct role in promoting vascular calcifica-
tion, however, there is now some evidence that the
increased level of FGF23 that occurs in CKD may lead to left
ventricular hypertrophy and CCF, independent of klo-
tho.65,66 These findings indicate that phosphate and FGF23
play distinct roles in the pathogenesis of CV disease in CKD
patients and future therapeutic strategies should target
both factors. In a rat model, the fibroblast growth factor-
receptor blockade has been shown to protect the animal
from FGF23-induced cardiac toxicity.66
Summary and conclusion
CRS is a growing health problem and is associated with high
morbidity and mortality. WRF during the treatment of ADHF
has been correlated with poor outcome. In HF, there are
different pathophysiological processes resulting in WRF,
each carrying different prognostic implications. This has led
to the specific examination of this outcome in the context
of clinical trials. The use of serum creatinine as a primary
end point was notoriously inadequate as a biomarker for
monitoring very short-term changes in GFR associated with
an hemodynamic effect. For example, a decline in kidney
function due to worsening HF is associated with poor
prognosis. By contrast, if the decline in kidney function
reflects adequate diuresis or decongestion, it has been
shown to improve outcomes.20,22 Similarly, in both SOLVD
and EPHESUS trials, early decline in renal function that
occurred during treatment with RAAS blockade or ACEI or
aldosterone blockers was associated with better outcome
compared with placebo.18,50,51
Although diuretics have been the main stay of treatment
for HF, the preferred mode of administration and dosing
remains unclear. Extrapolating the results from the DOSE
trial,23 high-dose loop diuretics given either in boluses or as
an infusion resulted in faster relief of dyspnea with greater
fluid and weight loss; however, it did not cause renal
adverse effect. Putting the results of the DOSE23 and
CARRESS-HF57 trials into perspective, a strategy for care of
patients with ADHF might comprise using accelerating loop
diuretic dose, possibly high-dose infusion over bolus
administration, with addition of oral metolazone, if
necessary, while reserving vasodilators, inotropes, and
salvage UF for more refractory cases, to improve symptoms
and decongest patients without necessarily compromising
the kidney function further.67 The benefit of ACEI/ARB/
aldosterone antagonists in HF is affirmed. However, thereare potential detrimental effects on serum potassium and
creatinine levels if more than two RAAS blockades are used,
making the addition of a renin inhibitor to dual ACEI/ARB
and aldosterone blocker difficult.48 In addition, many
vasoactive agents have been studied in the hope of aug-
menting cardiac function, improving symptoms and pa-
tients’ outcome while preserving renal function. Because
an important pathophysiological component in relation to
HF involves action of RAAS, adenosine, endothelin, and a
diminished response to NPs, there has been great interest
in targeting these maladaptive responses. The vasopressin
V2-receptor antagonist and nesiritide are being used as
adjuvant therapies to relieve acute dyspnea associated
with ADHF although larger-scale RCTs have failed to show
any medium- to long-term benefit.25,28,29 The novel agents,
ARNI, combining a neprilysin and an ARB, and serelaxin are
showing promising results. Levosimendan is a promising
treatment, which is an inotrope independent of the b-
adrenergic receptors; however, this has been showing
inconsistent results in the treatment of acute CRS. Further
studies are thus required to determine whether repetitive
dosing of levosimendan will benefit the survival of patients
with stable advanced CRS.
Many of the larger HF trials have demonstrated incon-
sistent results from earlier, smaller studies. This is partly
due to the heterogeneity of the underlying cardiac diseases
and EF, BP, and the different end points. The use of bio-
markers for early detection of renal injury in acute CRS is
still at an early stage and more research is required.12,13
Both UF and PD have been reserved for CRS patients
resistant to diuretics, however, their renal effect and long-
term outcomes are not clear. Future studies will need to
define the role of UF and PD in the management of CRS, and
shed light on aspects such as indications, patient selection,
dosing, and timing of start. Finally, in selected patients
with CRS, LVAD implant may improve renal function and
outcome. In the future, tackling of calcification in CKD
patients may provide new means to prevent CCF.
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